Figure 7.

Actinonin inhibits human tumor growth in xenograft mouse models. (A) Athymic nude mice bearing CWR22 human prostate tumor xenografts were treated with vehicle control (open circles), actinonin at 250 mg/kg i.p. (filled triangles), or actinonin at 500 mg/kg orally (filled squares) twice a day for 2 weeks (excluding weekends) as soon as s.c. tumors were palpable. Tumor size was measured every 3–5 days with calipers. Actinonin administered either i.p. or orally significantly inhibited the growth of the human prostate tumor xenografts (*P < 0.005). (B) Athymic nude mice bearing A549 human non–small cell lung cancer xenografts were treated with vehicle control (open circles) or actinonin at 150 mg/kg i.p. (filled triangles) once a day for 2 weeks (excluding weekends) as soon as s.c. tumors were palpable. Tumor size was measured every 3–5 days with calipers. Actinonin significantly inhibited the growth of the human lung cancer xenograft (**P < 0.01).